31 pharmaceutical companies line up A shares!

Medical News October 23 hearing As of October 19, 2017, a total of 31 pharmaceutical companies are lining up the IPO, but there are three drug companies IPO road was forced to terminate.

IPO crush of the three pharmaceutical companies are Gan Li medicine, Xi'an Bandung Pharmaceutical, Hefei Cube Pharmaceutical.

Which Gan Li medicine, IPO road to terminate the commercial bribery scandal behind, it is a temporary concern.

According to media reports, during the first IPO, Gan Li Pharmaceutical was involved in a commercial bribery scandal, caught in public opinion, which is also interpreted as the industry for the IPO process suspension reasons.

In September 2013, the media reported that Gan Li medicine medicine On behalf of the report Gan Li medicine at least from 2008 onwards began a commercial bribery.

The main object of its bribery is the major hospital Endocrine physician, and Gan Li medicine also developed a detailed rebate rules.

Commercial bribery scandal was exposed by the media, in January 2014, the media re-reported that the Hubei police officially arrested Gan Li medicine in Hubei 7Famous doctor Drug representatives, including provincial sales managers, regional managers and hospital representatives.

This Gan Li medicine responded that the commercial bribery in Hubei is a personal act.

However, according to Gan Li Pharmaceutical prospectus, 2013-2015, Gan Li pharmaceutical sales costs were 277 million yuan, 342 million yuan, 437 million yuan, the proportion of sales costs accounted for more than 35% of revenue.

Which accounted for the majority of business, publicity costs accounted for the majority of 2013 to 2015 the above costs were 170 million yuan, 219 million yuan, 263 million yuan, 3 years total 652 million yuan.

Shanghai Stock Exchange initial public offering of shares in the normal audit of the seven pharmaceutical companies, the Shenzhen Stock Exchange small board initial public offering of shares in the normal audit of the pharmaceutical companies 5, Shenzhen Stock Exchange Start a business Board of the initial public offering of shares in the normal audit of the pharmaceutical companies 5.

In addition to the normal audit of the 17 pharmaceutical companies, there are three enterprise Termination of the review. Two are due to the issuer to take the initiative to suspend the review or other audit work can not be carried out normally.

There is a result of the issuer is subject to suspicion of the subject or intermediary agency practice is limited so that the audit process can not continue.

In recent years, compared with the total number of enterprises queuing IPO, the number of pharmaceutical companies IPO is still relatively small.As of October 19, China Securities Regulatory Commission received a total of 569 starting companies, of which 37 have been, not the 532 The

Not in the enterprise will be 478 enterprises in the normal trial, suspended the review of 54 enterprises.

Serial number	Declare business	Sponsor	Approval Status
1	Beijing million Thai biological medicine	Country gold	Has feedback
2	Jiangxi Huiren Pharmaceutical	Haitong	Has feedback
3	Shenlian Biological Medicine (Shanghai)	Guoxin	Has feedback
4	Beijing Kang Chen Pharmaceutical	GF	Has feedback
5	Hainan Zhonghe Pharmaceutical	CITIC Investment	Has feedback
6	Suzhou Fu Shilai medicine	Hualin	Has feedback
7	Development of Wuxi WuXi PharmaTech	Huatai Union	Has been accepted
8	Stable medical supplies	Country gold	Has been voted on
9	Ningbo Tianyi medical equipment	Haitong	Has feedback
10	Zhende medical supplies	CITIC	Has feedback
11	Nanjing minimally invasive medical science and technology	CITIC Investment	Has feedback
12	Keke Hengtai (Beijing) Medical Technology	Great Wall	Has feedback
13	Medical industrial equipment	Guoxin	Has feedback
14	Jiangsu Weikang Jie Jing medical equipment	Debang	Has been accepted

Serial number	Declare business	Sponsor	Approval Status
15	Zhuhai Rundu Pharmaceuticals	The first business JP Morgan Chase	Has passed the Commission
16	Shaanxi Panlong Pharmaceutical Group *	China and Thailand	Has passed the Commission
17	Northern Wilminson Pharmaceuticals	Hualin	Pre-disclosed updates
18	Shenzhen Mindray Biomedical Electronics	BOC International	Has feedback
19	Zhejiang Anglangkang Pharmaceuticals	Oriental Citi	Has feedback
20	Wuhan Mingde Biotechnology	Country gold	Has feedback

Serial number	Declare business	Sponsor	Approval Status
21	Poinsettia medicine	GF	Has passed the Commission
22	Nanjing Pharmaceutical Stone Technology	CITIC Investment	Has passed the Commission
23	Nanjing Youke Biopharmaceutical Group	CITIC	Has feedback
24	Shanghai Meidi Biomedical Medicine	GF	Has been accepted
25	Guangdong Taien Kang medicine	northeast	Has been accepted
26	Shenzhen Lei Du Life Science	Merchants	Has feedback
27	Shenzhen new industry biomedical engineering	Huatai Union	Has feedback
28	Shenzhen Anjian Technology	Hualin	Has feedback
29	Shenzhen Besida Medical	Day wind	Has feedback
30	Zhonghongpu Lin medical supplies	Haitong	Has been accepted
31	Jiangsu Aiping Medical Technology	GF	Has been accepted

Suspended the review of 54 enterprises, suspended review is divided into the following circumstances:

Case 1, the application documents are not complete, etc. lead to the audit process can not continue;

Case II, the issuer of the main qualifications or suspicion of intermediary business practices led to the audit process can not continue;

Case 3, the issuer to disclose the information there is a question that requires further verification;

Case 4, the issuer to take the initiative to suspend the review or other audit work can not be carried out normally.

Serial number	Declare business	Sponsor	Approval Status
1	Hefei Cube Pharmaceuticals	Southwest Securities Co., Ltd	Discontinue review
2	Gan Li medicine	CITIC Securities Co., Ltd.	Discontinue review

Serial number	Declare business	Sponsor	Approval Status
3	Xi'an Bandung Pharmaceutical *	New era securities co., Ltd	Discontinue review